Neogenomics Inc
NASDAQ:NEO
Neogenomics Inc
NeoGenomics Inc. stands as a formidable player in the field of cancer diagnostics, carving out a niche where precision and innovation meet the urgent needs of patients and healthcare providers. Born out of the vision to advance cancer diagnostics through a blend of clinical testing and state-of-the-art technology, NeoGenomics offers oncologists and pathologists an extensive menu of tests that target genetic markers critical for cancer diagnosis and monitoring. The company operates through a network of high-complexity laboratories in the United States and a growing presence internationally, leveraging its vast technological capabilities to provide services like cytogenetics, molecular testing, and solid tumor testing. This breadth of service allows NeoGenomics to sit squarely at the intersection of patient care and the burgeoning field of personalized medicine.
By anchoring its revenue streams primarily in laboratory services, NeoGenomics draws its financial strength from a diverse clientele of community-based healthcare providers, academic institutions, and pharmaceutical companies. The firm capitalizes on the demand for precision diagnostics, as more treatments necessitate an intimate understanding of the tumor’s genetic makeup. This careful calibration between cutting-edge science and clinical practice not only fuels its growth but also positions NeoGenomics as an indispensable partner in the continuum of cancer care. Additionally, its collaborations with pharmaceutical companies open doors to new revenue channels via companion diagnostic development and clinical trial support services, exemplifying an agile approach in the dynamic landscape of oncology.
NeoGenomics Inc. stands as a formidable player in the field of cancer diagnostics, carving out a niche where precision and innovation meet the urgent needs of patients and healthcare providers. Born out of the vision to advance cancer diagnostics through a blend of clinical testing and state-of-the-art technology, NeoGenomics offers oncologists and pathologists an extensive menu of tests that target genetic markers critical for cancer diagnosis and monitoring. The company operates through a network of high-complexity laboratories in the United States and a growing presence internationally, leveraging its vast technological capabilities to provide services like cytogenetics, molecular testing, and solid tumor testing. This breadth of service allows NeoGenomics to sit squarely at the intersection of patient care and the burgeoning field of personalized medicine.
By anchoring its revenue streams primarily in laboratory services, NeoGenomics draws its financial strength from a diverse clientele of community-based healthcare providers, academic institutions, and pharmaceutical companies. The firm capitalizes on the demand for precision diagnostics, as more treatments necessitate an intimate understanding of the tumor’s genetic makeup. This careful calibration between cutting-edge science and clinical practice not only fuels its growth but also positions NeoGenomics as an indispensable partner in the continuum of cancer care. Additionally, its collaborations with pharmaceutical companies open doors to new revenue channels via companion diagnostic development and clinical trial support services, exemplifying an agile approach in the dynamic landscape of oncology.
Revenue Growth: NeoGenomics reported Q3 2025 revenue of $188 million, up 12% year-over-year and 4% sequentially, driven by strong clinical performance.
Clinical Business Strength: Clinical revenue grew by 18% year-over-year, and test volumes increased 15%, with robust gains from NGS and other modalities.
NGS Momentum: NGS revenue rose 24% year-over-year and now accounts for 33% of clinical revenue, far outpacing market growth.
Guidance Reiterated: Management maintained its full-year 2025 guidance for revenue ($720–726 million), adjusted EBITDA ($41–44 million), and net loss ($108–116 million).
New Product Launches: RaDaR ST MRD assay received a favorable court ruling and MolDX approval in two indications, setting up a broad clinical launch in Q1 2026; PanTracer LBx launched in July after a short delay.
Pathline Integration: The Pathline acquisition is on track and expected to accelerate growth and efficiencies in the Northeast region.
Margins & Profitability: Adjusted gross profit increased 7% year-over-year, and adjusted EBITDA was $12.2 million, marking the ninth consecutive positive quarter.
Pharma/Nonclinical Headwinds: Nonclinical revenue declined as expected; recovery in pharma is expected to be gradual, with a return to growth seen as a 2027 event.
Operational Investments: Ongoing investments in LIMS system upgrades and commercial expansion are expected to drive future efficiencies and growth.
